These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 11352728

  • 1. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
    Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM.
    Biochemistry; 2001 May 22; 40(20):5931-41. PubMed ID: 11352728
    [Abstract] [Full Text] [Related]

  • 2. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
    Gilbert HE, Eaton JT, Hannan JP, Holers VM, Perkins SJ.
    J Mol Biol; 2005 Feb 25; 346(3):859-73. PubMed ID: 15713468
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The 15 SCR flexible extracellular domains of human complement receptor type 2 can mediate multiple ligand and antigen interactions.
    Gilbert HE, Asokan R, Holers VM, Perkins SJ.
    J Mol Biol; 2006 Oct 06; 362(5):1132-47. PubMed ID: 16950392
    [Abstract] [Full Text] [Related]

  • 6. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
    Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD.
    J Immunol; 2001 Aug 01; 167(3):1490-9. PubMed ID: 11466369
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Solution structure of TT30, a novel complement therapeutic agent, provides insight into its joint binding to complement C3b and C3d.
    Li K, Gor J, Holers VM, Storek MJ, Perkins SJ.
    J Mol Biol; 2012 May 04; 418(3-4):248-63. PubMed ID: 22387467
    [Abstract] [Full Text] [Related]

  • 9. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
    Young KA, Chen XS, Holers VM, Hannan JP.
    J Biol Chem; 2007 Dec 14; 282(50):36614-25. PubMed ID: 17925391
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
    Hannan JP.
    Curr Protein Pept Sci; 2016 Dec 14; 17(5):463-87. PubMed ID: 26916158
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
    Isenman DE, Leung E, Mackay JD, Bagby S, van den Elsen JM.
    J Immunol; 2010 Feb 15; 184(4):1946-55. PubMed ID: 20083651
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
    Moore MD, Cannon MJ, Sewall A, Finlayson M, Okimoto M, Nemerow GR.
    J Virol; 1991 Jul 15; 65(7):3559-65. PubMed ID: 1645784
    [Abstract] [Full Text] [Related]

  • 19. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
    Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM.
    J Biol Chem; 2009 Apr 03; 284(14):9513-20. PubMed ID: 19164292
    [Abstract] [Full Text] [Related]

  • 20. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function.
    Henson SE, Smith D, Boackle SA, Holers VM, Karp DR.
    J Immunol Methods; 2001 Dec 01; 258(1-2):97-109. PubMed ID: 11684127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.